Adding immunotherapy to intensive chemotherapy shows promise in hard-to-treat colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Adding immunotherapy to intensive chemotherapy shows promise in hard-to-treat colorectal cancer — Nature Communications
The phase II NIVACOR trial tested nivolumab (an immunotherapy drug) combined with FOLFOXIRI/bevacizumab chemotherapy as first-line treatment in patients with RAS or BRAF-mutated metastatic colorectal cancer. These mutations